Le Lézard
Classified in: Health
Subjects: AWD, NPT, STP, AVO

New Jersey Senate to honor Partnership for a Drug-Free New Jersey Chair Elaine Pozycki


TRENTON, N.J., June 21, 2018 /PRNewswire-USNewswire/ -- The New Jersey Senate will be honoring Elaine Pozycki for her leadership in addressing New Jersey's opioid epidemic by presenting a resolution at 2 p.m. today at the Statehouse.

Partnership for a Drug-Free New Jersey Co-Chair Elaine Pozycki will be honored with a resolution by the New Jersey Senate for her leadership in combating New Jersey's opioid crisis.

Elaine, co-chair of the Partnership for a Drug-Free New Jersey, spearheaded the legislative efforts in New Jersey that resulted in the patient notification law, passed in February 2017, that now requires all New Jersey practitioners, prior to prescribing an opioid, to have a conversation with their patients on the addictive nature of the medications, as well possible non-opioid alternatives that are available.

The law also requires physicians, physician assistants, dentists and optometrists to complete one Continuing Medical Education credit on topics that include responsible prescribing practices, as well as risks and signs of opioid abuse, addiction and diversion.

"I am humbled and honored to receive this recognition and especially want to thank Senator Vitale and all the members of the New Jersey Senate for their support in the passage of the patient notification legislation that is saving lives every day in our state and nation," Pozycki said.

Realizing the need for the law to be enacted throughout the United States, Elaine and her husband, Steven, launched a national campaign called Prevent Opioid Abuse.

Versions of this groundbreaking legislation have now been adopted in five additional states (Rhode Island, Connecticut, Maryland, Nevada and Michigan) and are being considered by dozens of other state legislatures for adoption.

Best known for its statewide substance use prevention advertising campaign, the Partnership for a Drug-Free New Jersey is a private not-for-profit coalition of professionals from the communications, corporate and government communities whose collective mission is to reduce demand for illicit drugs in New Jersey through media communication. To date, more than $100 million in broadcast time and print space has been donated to the Partnership's New Jersey campaign, making it the largest public service advertising campaign in New Jersey's history. Since its inception the Partnership has garnered 166 advertising and public relations awards from national, regional and statewide media organizations.

SOURCE Partnership for a Drug-Free New Jersey


These press releases may also interest you

at 06:15
The "Molecular Diagnostics for Cancer: Markets Forecasts by Cancer Type, Product, and Place with Executive & Consultant Guides and Customization. 2023 to 2027" report has been added to  ResearchAndMarkets.com's offering. Exciting technical...

at 06:10
Confo Therapeutics, a leader in the discovery of novel medicines targeting G-protein coupled receptors (GPCRs), announced today that it has been awarded a EUR 1.6 million grant from Flanders Innovation & Entrepreneurship (VLAIO). The 2-year grant...

at 06:08
Aesthetic Management Partners LLC, a manufacturer of skin-based solutions and a provider of energy-based devices announces its collaboration with Croma (Croma-Pharma® GmbH), a global player in the minimally invasive aesthetics market and a leading...

at 06:05
The 2023 U.S. soybean field trials conducted by Texas Crop Science (TCS) demonstrated an average yield increase of 21% in soybean lines incorporating the TCS yield trait. This breakthrough in performance would generate approximately $121 per acre in...

at 06:05
3EO Health, a "Point of Life" diagnostics company focused on the development of high-performing low-cost molecular diagnostics, is excited to announce the next step in their quest to make molecular testing affordable. Today, the company has published...

at 06:05
Zura Bio Limited ("Zura Bio") a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today reported full year 2023 financial results and recent business highlights. The Company has also...



News published on and distributed by: